23/120
1.0 / 5 stars
All 120 Win/Lose results shown below
BHC Roast Me summary
Bausch Health Companies Inc. (BHC). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBHC / S&P -8.70% / 15.20% |
LoseBHC / S&P 10.09% / 15.00% |
LoseBHC / S&P -1238.46% / 50.40% |
| 2026-Q10/3 |
LoseBHC / S&P -22.30% / -4.33% |
LoseBHC / S&P 8.22% / 11.30% |
LoseBHC / S&P BHC unavailable / 27.70% |
| 2025-Q41/3 |
WinBHC / S&P 7.75% / 2.65% |
LoseBHC / S&P 6.66% / 9.00% |
LoseBHC / S&P BHC unavailable / 13.40% |
| 2025-Q31/3 |
LoseBHC / S&P -3.15% / 8.12% |
WinBHC / S&P 5.86% / 4.61% |
LoseBHC / S&P BHC unavailable / 13.45% |
| 2025-Q21/3 |
LoseBHC / S&P 2.94% / 10.94% |
WinBHC / S&P 7.13% / 4.83% |
LoseBHC / S&P BHC unavailable / 10.63% |
| 2025-Q11/3 |
LoseBHC / S&P -19.73% / -4.27% |
WinBHC / S&P 8.53% / 4.98% |
LoseBHC / S&P BHC unavailable / 10.57% |
| 2024-Q41/3 |
LoseBHC / S&P -1.23% / 2.41% |
WinBHC / S&P 9.91% / 5.25% |
LoseBHC / S&P BHC unavailable / 6.15% |
| 2024-Q32/3 |
WinBHC / S&P 17.07% / 5.89% |
WinBHC / S&P 10.91% / 5.89% |
LoseBHC / S&P BHC unavailable / 6.11% |
| 2024-Q21/3 |
LoseBHC / S&P -34.31% / 4.28% |
WinBHC / S&P 10.20% / 5.38% |
LoseBHC / S&P BHC unavailable / 5.12% |
| 2024-Q12/3 |
WinBHC / S&P 32.29% / 10.56% |
WinBHC / S&P 10.01% / 5.71% |
LoseBHC / S&P BHC unavailable / 5.59% |
| 2023-Q41/3 |
LoseBHC / S&P -2.43% / 11.69% |
WinBHC / S&P 7.79% / 6.81% |
LoseBHC / S&P BHC unavailable / 7.78% |
| 2023-Q31/3 |
WinBHC / S&P 2.75% / -3.27% |
LoseBHC / S&P 5.11% / 7.52% |
LoseBHC / S&P -471.83% / -5.03% |
| 2023-Q20/3 |
LoseBHC / S&P -1.23% / 8.74% |
LoseBHC / S&P 1.93% / 9.50% |
LoseBHC / S&P -492.31% / -8.57% |
| 2023-Q11/3 |
WinBHC / S&P 28.98% / 7.50% |
LoseBHC / S&P -2.10% / 10.77% |
LoseBHC / S&P BHC unavailable / -15.69% |
| 2022-Q40/3 |
LoseBHC / S&P -8.85% / 7.56% |
LoseBHC / S&P -3.68% / 11.88% |
LoseBHC / S&P BHC unavailable / -17.99% |
| 2022-Q30/3 |
LoseBHC / S&P -17.58% / -4.88% |
LoseBHC / S&P -3.83% / 13.47% |
LoseBHC / S&P BHC unavailable / -1.41% |
| 2022-Q20/3 |
LoseBHC / S&P -63.41% / -16.10% |
LoseBHC / S&P -3.37% / 13.71% |
LoseBHC / S&P BHC unavailable / 11.04% |
| 2022-Q10/3 |
LoseBHC / S&P -17.24% / -4.60% |
LoseBHC / S&P 3.52% / 15.97% |
LoseBHC / S&P BHC unavailable / 42.23% |
| 2021-Q40/3 |
LoseBHC / S&P -0.86% / 11.03% |
LoseBHC / S&P 5.07% / 15.00% |
LoseBHC / S&P BHC unavailable / 96.40% |
| 2021-Q30/3 |
LoseBHC / S&P -5.01% / 0.58% |
LoseBHC / S&P 5.14% / 10.77% |
LoseBHC / S&P BHC unavailable / 69.42% |
| 2021-Q20/3 |
LoseBHC / S&P -7.62% / 8.55% |
LoseBHC / S&P 4.55% / 6.58% |
LoseBHC / S&P BHC unavailable / 51.81% |
| 2021-Q11/3 |
WinBHC / S&P 52.60% / 6.17% |
LoseBHC / S&P -6.46% / -1.06% |
LoseBHC / S&P BHC unavailable / 7.39% |
| 2020-Q41/3 |
WinBHC / S&P 33.85% / 12.15% |
LoseBHC / S&P -6.67% / -3.72% |
LoseBHC / S&P BHC unavailable / -33.42% |
| 2020-Q30/3 |
LoseBHC / S&P -15.04% / 8.93% |
LoseBHC / S&P -5.41% / -2.04% |
LoseBHC / S&P BHC unavailable / -27.10% |
| 2020-Q20/3 |
LoseBHC / S&P 18.00% / 20.54% |
LoseBHC / S&P -3.75% / -0.46% |
LoseBHC / S&P BHC unavailable / -27.11% |
| 2020-Q10/3 |
LoseBHC / S&P -48.20% / -19.60% |
LoseBHC / S&P 2.33% / 3.47% |
LoseBHC / S&P BHC unavailable / -14.75% |
| 2019-Q41/3 |
WinBHC / S&P 36.93% / 9.07% |
LoseBHC / S&P 2.64% / 5.36% |
LoseBHC / S&P BHC unavailable / 2.99% |
| 2019-Q30/3 |
LoseBHC / S&P -13.36% / 1.70% |
LoseBHC / S&P 0.90% / 5.02% |
LoseBHC / S&P BHC unavailable / 0.21% |
| 2019-Q20/3 |
LoseBHC / S&P 2.11% / 4.30% |
LoseBHC / S&P -0.94% / 6.64% |
LoseBHC / S&P BHC unavailable / 8.65% |
| 2019-Q11/3 |
WinBHC / S&P 33.73% / 13.65% |
LoseBHC / S&P -2.43% / 8.12% |
LoseBHC / S&P BHC unavailable / 14.29% |
| 2018-Q40/3 |
LoseBHC / S&P -28.05% / -13.52% |
LoseBHC / S&P -3.94% / 9.05% |
LoseBHC / S&P -272.91% / 18.23% |
| 2018-Q31/3 |
WinBHC / S&P 10.46% / 7.71% |
LoseBHC / S&P -6.05% / 10.21% |
LoseBHC / S&P -341.03% / 19.06% |
| 2018-Q21/3 |
WinBHC / S&P 45.98% / 3.43% |
LoseBHC / S&P -7.79% / 9.03% |
LoseBHC / S&P BHC unavailable / 14.46% |
| 2018-Q10/3 |
LoseBHC / S&P -23.39% / -0.76% |
LoseBHC / S&P -8.51% / 7.68% |
LoseBHC / S&P BHC unavailable / 12.46% |
| 2017-Q41/3 |
WinBHC / S&P 45.01% / 6.64% |
LoseBHC / S&P -9.82% / 7.03% |
LoseBHC / S&P BHC unavailable / 13.82% |
| 2017-Q30/3 |
LoseBHC / S&P -17.17% / 4.48% |
LoseBHC / S&P -10.62% / 5.68% |
LoseBHC / S&P BHC unavailable / 17.57% |
| 2017-Q21/3 |
WinBHC / S&P 56.84% / 3.09% |
LoseBHC / S&P -10.76% / 4.83% |
LoseBHC / S&P BHC unavailable / 17.74% |
| 2017-Q10/3 |
LoseBHC / S&P -24.04% / 6.07% |
LoseBHC / S&P -11.62% / 3.67% |
LoseBHC / S&P BHC unavailable / 13.32% |
| 2016-Q40/3 |
LoseBHC / S&P -40.86% / 3.82% |
LoseBHC / S&P -7.40% / 2.09% |
LoseBHC / S&P BHC unavailable / 7.05% |
| 2016-Q32/3 |
WinBHC / S&P 21.90% / 3.85% |
WinBHC / S&P 1.05% / 0.20% |
LoseBHC / S&P -471.19% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BHC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -14.69% | 20.78% |
| Annualized return | -14.69% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BHC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -78.06% | 83.14% |
| Annualized return | -26.17% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | BHC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -78.26% | 319.30% |
| Annualized return | -14.15% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |